Loading articles...
Outsmarting Shape-Shifting Lung Cancer Resistance
Resistance to EGFR inhibitors is almost inevitable — but the mechanisms are predictable and increasingly targetable. From T790M acquired resistance to osimertinib, through FLAURA2 combination strategies, Sarah Mitchell and James Carter explain how the field...
Targeted ADCs For Advanced Lung Cancer
Antibody-drug conjugates have redefined what targeted therapy means in lung cancer. Trastuzumab deruxtecan in HER2-mutant NSCLC and datopotamab deruxtecan in TROP2-expressing disease are producing responses that older chemotherapy could not approach. Sarah ...
How Immunotherapy Unmasks Invisible Lung Cancer
PD-L1 expression is the gatekeeper to first-line immunotherapy in NSCLC — but the biology of why some tumours respond and others do not remains one of oncology's central questions. Sarah Mitchell and James Carter examine the landmark trials that established...
Hacking the Lung Cancer Genetic Code
EGFR, ALK, ROS1, KRAS — lung cancer has more targetable mutations than any other solid tumour. Sarah Mitchell and James Carter unpack how genomic profiling transformed NSCLC from a single disease into a collection of precision targets, and what each mutatio...
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
ATS 2026 highlights the persistent gap in objective cough assessment in respiratory diseases, hindering precise diagnosis and treatment efficacy.
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
Integrating AI for lung cancer prediction into multidisciplinary team workflows demonstrates operational improvements and potential for enhanced patient stratification.
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
ATS 2026 highlights evolving lung cancer management, focusing on precision medicine and novel targeted therapies for improved patient outcomes.
Does Vaping Cause Cancer? What the 2025–26 Evidence Shows
Three new papers assess carcinogenicity, toxicant exposure, and oral microbiota changes in vapers. The evidence is concerning but incomplete.